Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Posaconazole IV and PFS in Pediatric Participants With Invasive Fungal Infection
NCT04665037Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2022
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of posaconazole in invasive fungal infection (IFI), sponsored by Merck & Co.. Started Feb 2022; status: recruiting.
02
Drugs
posaconazole
03
Conditions
invasive fungal infection (IFI)
Beyond the preview
Go deeper on NCT04665037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04665037.